Planning Grant: I/UCRC for a New Site within the Center for Pharmaceutical Development

该提案要求为特拉华大学（UDEL）加入药物开发中心（CPD）提供资金。CPD的佐治亚理工学院是牵头机构，而肯塔基大学是一个“合作伙伴”网站。特拉华大学拟议的I/UCRC站点将在生物制药开发创新的核心技术领域为现有的药物开发中心（CPD）带来世界级的专业知识。这些领域目前尚不存在或仅占CPD专业知识的一小部分，并将使CPD能够建立其优势，专注于开发小分子药物，工业酶和相关生物技术产品；使扩展后的CPD成为一个更强大、更有影响力的I/UCRC。该中心的教师是世界公认的领导者，将为目前的CPD提供新的优势，补充现有的固态药物稳定性和输送、工业酶和相关生物技术产品开发方面的专业知识。扩大后的CPD将是迄今为止影响最深远的产学研联盟，专注于药品开发，而不是发现研究或临床开发。它将解决的项目领域有可能大大提高药物开发研究和工程的效率和经济性，以及对该行业工程师和科学家的基本理解和教育。这可以在创造国内就业机会、缩短上市时间、降低患者成本、降低投资者开发和测试新治疗性蛋白质（UD Site的重点）和创新药物（CPD总体的重点）的风险等方面广泛地造福美国。这些项目将涉及来自科学和工程领域代表性不足群体的学生，包括通过内部资助或通过补充联邦资助的研究实习。

The proposal requests funding for the University of Delaware (UDEL) to join the Center for Pharmaceutical Development (CPD). Georgia Tech at CPD is the lead institution, while the University of Kentucky Is a 'Partner' site. The proposed I/UCRC Site at the University of Delaware will bring world-class expertise to an existing Center for Pharmaceutical Development (CPD) in technical areas that are central to biopharmaceutical development innovation. These areas are currently absent or represent only a small portion of the expertise within the CPD, and will enable the CPD to build upon its strengths focused on development of small-molecule pharmaceuticals, industrial enzymes, and related biotechnology products; making the expanded CPD an even more robust and high-impact I/UCRC. The faculty in the proposed Site for the CPD are world-recognized leaders, and will provide new strengths to the current CPD that complements the existing expertise in solid-state pharmaceutical stability and delivery, and development of industrial enzymes and related biotechnology products. The proposed, expanded CPD will be the most far-reaching industry-university consortium to date that is focused on pharmaceutical product development, rather than discovery research or clinical development. The project areas it will address have the potential to greatly improve the efficiency and economics of drug development research and engineering, as well as the fundamental understanding and education of engineers and scientists in the industry. This can benefit the U.S. broadly in terms of domestic job creation, as well as improved time to market, cost to patients, and reduced risk for investors for the development and testing of new therapeutic proteins (focus of UD Site) and innovator pharmaceuticals more generally (focus of CPD overall). The PIs will involve students from underrepresented groups in science and engineering, including through research internships that are funded internally or through complementary federal funding.